Press Releases

GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). With the approval by MFDS, BARYTHRAX has become Korea's 39th novel drug. Following the application on 31 Oct. 2023, GC Biopharma and KDCA successfully received the product approval from MFDS on 8th this month. Anthrax, caused by Bacillus anthracis, is

Orexo AB, today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The aim of the collaboration is to develop mucosal vaccines by combining Orexo's powder-based drug delivery technology AmorphOX with Abera's innovative and patented vaccine platform BERA™. T

Valneva SE, a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis. Shigellosis is the second leading cause of fatal diarrheal disease worl

AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® for the treatment of giant cell arteritis (GCA) in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA. "GCA is a challenging and often debilitating condition. Patients may endure headaches, jaw pain and muscle aches, with many fearing sudden and permanen

LOG Pharma Primary Packaging, a leading global provider of innovative packaging solutions for the pharmaceutical industry, offers drug manufacturers a complete, integrated packaging solution. By producing both bottles and caps at the same facility, LOG is ensuring unmatched compatibility, reducing waste, and creating confidence in packaging Traditionally, pharmaceutical companies source drug bottles from one supplier and closures from another. This approach often leads to mismatched

Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, announced its plan to accelerate development of its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology. The company has completed in vivo proof-of-concept studies and expects to file an Investigational New Drug (IND) application in 2026. SOOPR is a rapid-onse

NeuroSense Therapeutics, Ltd. a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced that two members of its Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting. The presentations and conference will be taking place in San Diego, CA on April 8, 2025. Jere

The participation of governmental bodies and research institutions is an important element of the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2025. As the industry navigates significant issues such as data security risks, supply chain complexities and sustainability pressures, these organisations bridge the gap between drug producers and society by conveying its needs and priorities. Scheduled for 14-15 April in

ABEC, a global leader in engineered solutions and services for biotechnology manufacturing, has introduced its Advanced Therapy Bioreactor (ATB™), a revolutionary platform focused on transforming cell expansion for Advanced Therapy Medicinal Products (ATMPs). Designed to overcome the limitations of currently available systems, the ATB™ delivers unparalleled process control and scalability from design to commercialization. The ATB™ redefines cell culture by mimickin

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), generalized myasthenia gravis (gMG), and thymidine kinase 2 deficiency (TK2d), at this year's American Academy of Neurology (AAN) meeting, San Diego, California, April 5-9, 2025. "We at UCB are deeply committed to driving innovation to improve the treatment and care of